Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
FAIL · Does not pass the screen
42.21 USD
At the last full screen 2026-09-16
Screened 2026-09-16 · the tape above runs as of 21:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Harmony Biosciences Holdings, Inc. holds its Accumulation at $42.21. The statistical read favours the buyers, held for 47 days.
As held on the ledger · 2026-09-16
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 47 days
Price at the screen
$42.21
Valuation
13.66 trailing · 6.31 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.93
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
12.87%
Below 33%
Interest-bearing debt is just 12.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
8.42%
Below 33%
Cash held in interest-bearing accounts and securities is 8.4% of assets, under the one-third limit.
Pass
Receivables
66.79%
Below 49%
Money owed to the company is 66.8% of assets, above the 49% limit.
Fail
Revenue purity
2.52%
Below 5%
Only 2.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-16 screen. The gold marker is the market price at the same screen. A 48.1% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Buy. The average target sits +18% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-16 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Rare Disease Drugmaker Trades At A Steep Discount
A patient with narcolepsy who finally sleeps through the night thanks to one approved pill shows how focused biotechs can turn rare conditions into steady revenue. Harmony Biosciences already sells WAKIX at a 17 percent revenue growth rate, delivers 16 percent profit margins and posts 18 percent return on equity, all while clearing our ethical screen without issue. The forward price to earnings ratio of just 5.6 times leaves plenty of room before it matches the 43 dollar analyst median target.
Yet the moat remains unknown and the business sits in a sector where one regulatory setback or fresh competitor can erase years of progress. That combination explains the none rating despite the 59 percent gap between the current 33.77 dollar price and our fair value estimate. High volatility around single-product exposure keeps the overall risk elevated.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HRMY trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 18.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (11 analysts) rates it none, with a mean price target of $44.
2026-08-01Markup · changed$33.77-2.0%Entry 4
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (11 analysts) rates it none, with a mean price target of $44.
2026-07-18Markdown$34.46+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (11 analysts) rates it none, with a mean price target of $44.
2026-07-03Markdown$34.46+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markdown$34.46Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
